This article was originally published in The Rose Sheet
First quarter fragrance sales decline 1.8% in Swiss Francs, or .3% in local currencies to $214.5 mil. (1 CHF=$0.77) due to discontinued sales of commodity ingredients, firm reports. Fine fragrances, however, experienced double-digit growth in local currencies driven by the launches of several prestige fragrances. Total sales in the quarter grew 2.4% in Swiss Francs, or 4.1% in local currencies, to $540.5 mil. Givaudan will continue to focus on developing proprietary fragrance ingredients this year, the company said during its annual investor meeting April 8. Among the exclusive ingredients Givaudan plans to launch is Toscanol, a replacement for Estragole, which has been found to be a naturally occurring genotoxic carcinogen. The company also will introduce Javanol, a sandalwood odorant at the World Perfumery Congress June 1-5 in Cannes, France, according to Givaudan Head of Fragrance Chemistry Markus Gautschi...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.